160 related articles for article (PubMed ID: 17626246)
21. Androgen deprivation therapy caused a drastic proliferation of B-cell lymphoma with IgG4-related disease in patients with prostate cancer: a case report.
Sasagawa H; Numakura K; Mori M; Kobayashi M; Kashima S; Yamamoto R; Nara T; Saito M; Narita S; Nanjo H; Habuchi T
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15091-15094. PubMed ID: 37688628
[TBL] [Abstract][Full Text] [Related]
22. Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer.
Nordeen SK; Su LJ; Osborne GA; Hayman PM; Orlicky DJ; Wessells VM; van Bokhoven A; Flaig TW
Life (Basel); 2021 Aug; 11(9):. PubMed ID: 34575033
[TBL] [Abstract][Full Text] [Related]
23. Characterization of iPS87, a prostate cancer stem cell-like cell line.
Assoun EN; Meyer AN; Jiang MY; Baird SM; Haas M; Donoghue DJ
Oncotarget; 2020 Mar; 11(12):1075-1084. PubMed ID: 32256979
[TBL] [Abstract][Full Text] [Related]
24. Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years.
Shida Y; Hakariya T; Miyata Y; Sakai H
Clin Case Rep; 2017 Apr; 5(4):425-428. PubMed ID: 28396761
[TBL] [Abstract][Full Text] [Related]
25. Endocrine manipulations in cancer prostate: A review.
Rajput R; Sehgal A
Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S199-204. PubMed ID: 23565378
[TBL] [Abstract][Full Text] [Related]
26. Cardiac and cognitive effects of androgen deprivation therapy: are they real?
Alibhai SM; Mohamedali HZ
Curr Oncol; 2010 Sep; 17 Suppl 2(Suppl 2):S55-64. PubMed ID: 20882135
[TBL] [Abstract][Full Text] [Related]
27. Relugolix - The novel oral androgen deprivation therapy for prostate cancer.
Jena R
Indian J Urol; 2020; 36(4):327-328. PubMed ID: 33376275
[No Abstract] [Full Text] [Related]
28. Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate Cancer.
Churchill TW; Smith MR; Michaelson MD; Lee RJ; Guseh JS; Wasfy MM; Meneely E; Olivier K; Baggish AL; Saylor PJ
J Am Soc Echocardiogr; 2024 Mar; ():. PubMed ID: 38499230
[No Abstract] [Full Text] [Related]
29. The Emerging and Promising Role of Care for Cardiometabolic Syndrome in Prostate Cancer.
Tanaka A; Node K
JACC CardioOncol; 2019 Dec; 1(2):307-309. PubMed ID: 34396197
[No Abstract] [Full Text] [Related]
30. The history of intermittent androgen deprivation therapy - A Canadian story.
Klotz L
Can Urol Assoc J; 2020 Jun; 14(6):159-162. PubMed ID: 32525797
[No Abstract] [Full Text] [Related]
31. Androgen deprivation therapy.
Hoffman P; Djavan B
Rev Urol; 2008; 10(4):305-6. PubMed ID: 19145276
[No Abstract] [Full Text] [Related]
32. Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.
Filon MJ; Gillette AA; Yang B; Khemees TA; Skala MC; Jarrard DF
Prostate; 2022 Dec; 82(16):1547-1557. PubMed ID: 35980831
[TBL] [Abstract][Full Text] [Related]
33.
Mukherjee A; Park A; Davies KP
J Mens Health; 2022 Feb; 18(2):. PubMed ID: 35547856
[TBL] [Abstract][Full Text] [Related]
34. Androgen Deprivation Induces Reprogramming of Prostate Cancer Cells to Stem-Like Cells.
Sánchez BG; Bort A; Vara-Ciruelos D; Díaz-Laviada I
Cells; 2020 Jun; 9(6):. PubMed ID: 32531951
[TBL] [Abstract][Full Text] [Related]
35. A Novel Tanshinone Analog Exerts Anti-Cancer Effects in Prostate Cancer by Inducing Cell Apoptosis, Arresting Cell Cycle at G2 Phase and Blocking Metastatic Ability.
Wang M; Zeng X; Li S; Sun Z; Yu J; Chen C; Shen X; Pan W; Luo H
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510010
[TBL] [Abstract][Full Text] [Related]
36. Proteomic analysis of human prostate cancer PC-3M-1E8 cells and PC-3M-2B4 cells of same origin but with different metastatic potential.
Zhang S; Zheng C; Yao S; Wang Z; Xu L; Yang R; Meng X; Wu J; Zhou L; Sun Z
PLoS One; 2018; 13(10):e0206139. PubMed ID: 30379883
[TBL] [Abstract][Full Text] [Related]
37. Prolonged androgen deprivation leads to overexpression of calpain 2: implications for prostate cancer progression.
Liu T; Mendes DE; Berkman CE
Int J Oncol; 2014 Feb; 44(2):467-72. PubMed ID: 24297527
[TBL] [Abstract][Full Text] [Related]
38. From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells.
Liu T; Mendes DE; Berkman CE
Int J Oncol; 2013 Oct; 43(4):1125-30. PubMed ID: 23877345
[TBL] [Abstract][Full Text] [Related]
39. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells.
Liu T; Wu LY; Fulton MD; Johnson JM; Berkman CE
Int J Oncol; 2012 Dec; 41(6):2087-92. PubMed ID: 23041906
[TBL] [Abstract][Full Text] [Related]
40. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
